Literature DB >> 11862219

Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera.

Sofia Casares1, Alicia Hurtado, Robert C McEvoy, Adelaida Sarukhan, Harald von Boehmer, Teodor-Doru Brumeanu.   

Abstract

Type 1 diabetes is an organ-specific autoimmune disease that is mediated by autoreactive T cells. We show here that administration of a soluble dimeric peptide-major histocompatibility complex (pMHC) class II chimera (DEF) to prediabetic double-transgenic mice prevents the onset of disease or, in animals that are already diabetic, restores normoglycemia. The antidiabetogenic effects of DEF rely on the induction of anergy in splenic autoreactive CD4+ T cells via alteration of early T cell receptor signaling and stimulation of interleukin 10-secreting T regulatory type 1 cells in the pancreas. Soluble dimeric pMHC class II may be useful in the development of immunospecific therapies for type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862219     DOI: 10.1038/ni770

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  33 in total

1.  High-throughput engineering and analysis of peptide binding to class II MHC.

Authors:  Wei Jiang; Eric T Boder
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-09       Impact factor: 11.205

Review 2.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

3.  Functional avidity directs T-cell fate in autoreactive CD4+ T cells.

Authors:  Roberto Mallone; Sharon A Kochik; Helena Reijonen; Bryan Carson; Steven F Ziegler; William W Kwok; Gerald T Nepom
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

Review 4.  Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?

Authors:  Xavier Clemente-Casares; Sue Tsai; Yang Yang; Pere Santamaria
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

5.  Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display.

Authors:  Fei Wen; Dhruv K Sethi; Kai W Wucherpfennig; Huimin Zhao
Journal:  Protein Eng Des Sel       Date:  2011-07-13       Impact factor: 1.650

6.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.

Authors:  Eliane Piaggio; Lennart T Mars; Cécile Cassan; Julie Cabarrocas; Maria Hofstätter; Sabine Desbois; Emilie Bergereau; Olaf Rötzschke; Kirsten Falk; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

7.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Double negative (CD3+ 4- 8-) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes.

Authors:  Beverly Duncan; Cristina Nazarov-Stoica; Jacqueline Surls; Margaret Kehl; Constantin Bona; Sofia Casares; Teodor-D Brumeanu
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

10.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.